These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes. Prescrire Int; 2009 Jun; 18(101):104. PubMed ID: 19637415 [TBL] [Abstract][Full Text] [Related]
27. [Efficacy of atazanavir in simplification regimens]. Zamora L; Gatell JM Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():14-21. PubMed ID: 20116612 [TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients. Squires KE; Young B; DeJesus E; Bellos N; Murphy D; Sutherland-Phillips DH; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS; HIV Clin Trials; 2010; 11(2):69-79. PubMed ID: 20542844 [TBL] [Abstract][Full Text] [Related]
29. Simplified maintenance therapy with abacavir/lamivudine and atazanavir after discontinuation of ritonavir. Elion R; Berger D; Richmond G; Sension M; Dejesus E; Cimoch P; St Clair M; Yau L; Ha B; HIV Clin Trials; 2010; 11(3):170-3. PubMed ID: 20736153 [No Abstract] [Full Text] [Related]
30. Drug interactions. Is atazanavir best when boosted with ritonavir? TreatmentUpdate; 2006; 18(3):3. PubMed ID: 17209237 [No Abstract] [Full Text] [Related]
31. The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients. Chetchotisakd P Expert Rev Anti Infect Ther; 2009 Sep; 7(7):801-5. PubMed ID: 19735222 [TBL] [Abstract][Full Text] [Related]
32. CASTLE study showed similar efficacy. AIDS Patient Care STDS; 2008 Mar; 22(3):253. PubMed ID: 18348342 [No Abstract] [Full Text] [Related]
33. Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results. Gallant JE; Koenig E; Andrade-Villanueva JF; Chetchotisakd P; DeJesus E; Antunes F; Arastéh K; Rizzardini G; Fehr J; Liu HC; Abram ME; Cao H; Szwarcberg J J Acquir Immune Defic Syndr; 2015 Jul; 69(3):338-40. PubMed ID: 26181707 [TBL] [Abstract][Full Text] [Related]
34. Atazanavir in patients with persistent viral replication despite HAART: results from the French prospective NADIS cohort. Cuzin L; Flandre P; Pugliese P; Duvivier C; Yazdanpanah Y; Billaud E; Poizot-Martin I; Katlama C; HIV Clin Trials; 2008; 9(3):147-51. PubMed ID: 18547901 [TBL] [Abstract][Full Text] [Related]
35. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice. Moltó J; Santos JR; Valle M; Miranda C; Miranda J; Blanco A; Negredo E; Clotet B Ther Drug Monit; 2007 Oct; 29(5):648-51. PubMed ID: 17898658 [TBL] [Abstract][Full Text] [Related]
36. Interaction between atazanavir and fosamprenavir in the treatment of HIV-infected patients. Khanlou H; Bhatti L; Farthing C J Acquir Immune Defic Syndr; 2006 Jan; 41(1):124-5. PubMed ID: 16340485 [No Abstract] [Full Text] [Related]
37. [Insulin resistance in HIV-infected patients receiving long-term therapy with efavirenz, lopinavir/ritonavir and atazanavir]. Bernal E; Masiá M; Padilla S; Ramos JM; Martín-Hidalgo A; Gutiérrez F Med Clin (Barc); 2007 Jul; 129(7):252-4. PubMed ID: 17683706 [TBL] [Abstract][Full Text] [Related]
38. Changes in kidney function in patients with suppressed HIV RNA who substitute their protease inhibitor with atazanavir/ritonavir. Hamzah L; Campbell L; Wandolo E; Engler B; Cheserem E; Naftalin C; Taylor C; Post FA AIDS; 2015 Jan; 29(3):392-4. PubMed ID: 25686688 [No Abstract] [Full Text] [Related]
39. Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers. Dickinson L; Boffito M; Back D; Waters L; Else L; Davies G; Khoo S; Pozniak A; Aarons L J Antimicrob Chemother; 2009 Jun; 63(6):1233-43. PubMed ID: 19329800 [TBL] [Abstract][Full Text] [Related]